CMPX vs. ETNB, ANIP, MESO, EWTX, JANX, TVTX, CVAC, CALT, GPCR, and AUPH
Should you be buying Compass Therapeutics stock or one of its competitors? The main competitors of Compass Therapeutics include 89BIO (ETNB), ANI Pharmaceuticals (ANIP), Mesoblast (MESO), Edgewise Therapeutics (EWTX), Janux Therapeutics (JANX), Travere Therapeutics (TVTX), CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Structure Therapeutics (GPCR), and Aurinia Pharmaceuticals (AUPH). These companies are all part of the "pharmaceutical products" industry.
Compass Therapeutics vs. Its Competitors
89BIO (NASDAQ:ETNB) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.
68.4% of Compass Therapeutics shares are held by institutional investors. 2.8% of 89BIO shares are held by insiders. Comparatively, 29.8% of Compass Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Compass Therapeutics has higher revenue and earnings than 89BIO. Compass Therapeutics is trading at a lower price-to-earnings ratio than 89BIO, indicating that it is currently the more affordable of the two stocks.
Compass Therapeutics' return on equity of -42.47% beat 89BIO's return on equity.
In the previous week, Compass Therapeutics had 3 more articles in the media than 89BIO. MarketBeat recorded 3 mentions for Compass Therapeutics and 0 mentions for 89BIO. Compass Therapeutics' average media sentiment score of 0.86 beat 89BIO's score of 0.00 indicating that Compass Therapeutics is being referred to more favorably in the news media.
89BIO currently has a consensus price target of $26.43, suggesting a potential upside of 158.60%. Compass Therapeutics has a consensus price target of $12.67, suggesting a potential upside of 379.80%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Compass Therapeutics is more favorable than 89BIO.
89BIO has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500.
Summary
Compass Therapeutics beats 89BIO on 13 of the 15 factors compared between the two stocks.
Get Compass Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CMPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Compass Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CMPX) was last updated on 7/7/2025 by MarketBeat.com Staff
Free CMPX Stock Alerts